Emeryville, Calif. — OmniAb, Inc. has appointed Amechi Nwachuku as executive vice president and chief operating officer, a newly created position focused on expanding the company’s xPloration single B-cell screening platform.
Nwachuku will oversee strategy, operations and commercial development for xPloration, OmniAb’s proprietary high-throughput platform used in antibody discovery.
He brings more than 25 years of experience leading global life sciences tools businesses. Most recently, he served as vice president of Global Commercial Genetic Sciences at Thermo Fisher Scientific. He previously held senior commercial and executive roles at SCIEX, Beckman Coulter Diagnostics, Johnson & Johnson Diabetes Care and Bayer.
Earlier in his career, Nwachuku worked as a management consultant at McKinsey & Company. He holds a bachelor’s degree in chemical engineering and an MBA from the Massachusetts Institute of Technology.
“Amechi is a seasoned global leader whose extensive experience and perspectives will further strengthen our executive management team,” said Matt Foehr, president and chief executive officer of OmniAb. “Throughout his career, Amechi has established a proven track record of commercial and operational excellence, consistently driving growth, capitalizing on market opportunities, and efficiently creating value.”
Foehr said OmniAb sees xPloration as a complement to its core antibody discovery technology licensing business, with the potential to expand growth opportunities and diversify future revenue.
“I am excited to join the innovative team at OmniAb, which has already demonstrated the power of its xPloration platform and its potential to make a meaningful impact in the lab,” Nwachuku said. “My enthusiasm only grew as I learned more about the company, its differentiated technologies and the growth potential of xPloration, designed to meet the industry’s growing demand for large datasets and reliable, easy-to-use, high-throughput screening.”
The AI-powered xPloration platform is designed to examine millions of antibody-secreting cells and rapidly recover thousands of antibody sequences. OmniAb said the technology can improve antibody discovery efficiency through large-scale repertoire mining and functional screening assays.
